GOSS
The clock is ticking
Gossamer Bio is back in the spotlight, but not for a breakthrough. Faruqi & Faruqi is reminding investors that June 1, 2026 is the deadline to join a securities class action tied to the company’s February disclosure that its Phase 3 PROSERA study missed its primary endpoint.
What set this off?
The complaint centers on allegations that Gossamer and certain executives made misleading statements, or left out key details, about the study design and how it controlled for placebo response at Latin American sites. Then came the Feb. 23 readout: the trial showed a placebo-adjusted gain of 13.3 meters in six-minute walk distance, but that wasn’t enough to clear the prespecified statistical bar.
Why investors should care
This isn’t just legal theater. Securities class actions can drag on for months, cost real money, and keep a fresh scar on the stock chart. And when a biotech trial disappoints this badly — especially after shares reportedly slid from $2.13 to $0.42 in a day — the market tends to treat every follow-up notice like another reminder that the story is still broken.
Big picture: the science may have missed, and now the lawsuit is making sure investors don’t forget it.